Intervention not reported
Patients with ≥ 1 exacerbations requiring oral corticosteroids Duration of trials: 6 to 16 weeks · adults and adolescents with persistent asthma
The intervention probably leads to lower patients with ≥ 1 exacerbations requiring oral corticosteroids… (moderate certainty).
1 finding from 1 review
Intervention not reported
Participants with ≥ 1 exacerbation requiring oral corticosteroids Duration of trials: 8 to 24 weeks · adults and adolescents with persistent asthma
The intervention showed no clear difference in participants with ≥ 1 exacerbation requiring oral corticosteroids… (low certainty).
1 finding from 1 review
Intervention not reported
Patients with ≥ 1 exacerbation requiring oral corticosteroids Duration of trials: 8 to 13 weeks · adults and adolescents with persistent asthma
The intervention showed no clear difference in patients with ≥ 1 exacerbation requiring oral corticosteroids… (moderate certainty).
1 finding from 1 review
Intervention not reported
Exacerbations requiring oral corticosteroids 48 weeks · adults with asthma
The intervention showed no clear difference in exacerbations requiring oral corticosteroids 48 weeks (moderate certainty).
1 finding from 1 review
Intervention not reported
Number of participants with exacerbations requiring systemic steroids · children with chronic asthma
The intervention showed no clear difference in number of participants with exacerbations requiring systemic steroids (moderate certainty).
1 finding from 1 review
Intervention not reported
Number of participants with exacerbations requiring systemic steroids · children with chronic asthma
The intervention showed no clear difference in number of participants with exacerbations requiring systemic steroids (moderate certainty).
1 finding from 1 review
Rate of exacerbations requiring systemic corticosteroids · adults with asthma well controlled on LABA and ICS
Stopping LABA showed no clear difference in exacerbation: systemic corticosteroids 17 weeks compared with continuing use of LABA+ICS (moderate certainty).
1 finding from 1 review
Exacerbations (OCS) · adults with asthma not well controlled on ICS
LAMA add‐on leads to lower exacerbations requiring oral corticosteroids (OCS) compared with ICS alone (high certainty).
1 finding from 1 review
Number of participants with exacerbations requiring systemic steroids · patients with chronic asthma
LABA + ICS leads to lower participants with one or more exacerbations requiring systemic… compared with LTRA + ICS (high certainty).
1 finding from 1 review
Number of participants experiencing one or more episode requiring treatment with oral steroids · children with asthma
Anti‐leukotrienes & ICS may leads to lower participants with one or more exacerbations requiring oral… compared with same dose ICS (low certainty).
1 finding from 1 review
Number of participants experiencing one or more episode requiring treatment with oral steroids · children with asthma
Anti‐leukotrienes & ICS may leads to lower participants with one or more exacerbations requiring oral… compared with higher dose ICS (low certainty).
1 finding from 1 review
Number of participants experiencing one or more episode requiring treatment with oral steroids · Children and adults with persistent asthma.
Intermittent 'as needed' ICS showed no clear difference in patients with 1 or more exacerbations requiring oral corticosteroids… compared with daily ICS (low certainty).
1 finding from 1 review
Exacerbations · autumn asthma exacerbations in children
A boost of inhaled corticosteroids showed no clear difference in exacerbations compared with usual care (moderate certainty).
1 finding from 1 review
Adverse events · autumn asthma exacerbations in children
A boost of inhaled corticosteroids showed no clear difference in adverse events compared with usual care (moderate certainty).
1 finding from 1 review
Rate of exacerbations requiring systemic corticosteroids · children and adults with predominantly mild to moderate asthma
Summary of findings table ‐ Vitamin D showed no clear difference in proportion of participants with one or more exacerbations treated… compared with placebo (high certainty).
1 finding from 1 review
Rate of clinically significant exacerbations requiring systemic corticosteroids · people with asthma
Mepolizumab subcutaneous (SC) leads to lower rate of clinically significant exacerbations requiring systemic… compared with placebo (high certainty).
1 finding from 1 review
Rate of clinically significant exacerbations requiring systemic corticosteroids · people with asthma
Reslizumab intravenous (IV) leads to lower rate of clinically significant exacerbations requiring systemic… compared with placebo (high certainty).
1 finding from 1 review
Rate of clinically significant exacerbations requiring systemic corticosteroids · people with asthma
Reslizumab subcutaneous (SC) showed no clear difference in rate of clinically significant exacerbations requiring systemic… compared with placebo (high certainty).
1 finding from 1 review
Rate of clinically significant exacerbations requiring systemic corticosteroids · people with asthma
Benralizumab subcutaneous (SC) leads to lower rate of clinically significant exacerbations requiring systemic… compared with placebo (high certainty).
1 finding from 1 review
Rate of clinically significant exacerbations requiring systemic corticosteroids · people with asthma
Mepolizumab intravenous (IV) leads to lower rate of clinically significant exacerbations requiring systemic… compared with placebo (high certainty).
1 finding from 1 review